January 16, 2003

0880 '03 MAR -3 P1:52

FTR (12 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	While POAs support immune health,* tetracyclic oxindole alkaloids have decidedly different effects in the body, none supporting immune system cells.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/16/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely, . Nevern

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Michael P. Devereux Chief Financial Officer

975 0162

LET /1420

83270

Celle Forte Max3 27e

January 3, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

-	~	-			~
ţ	۰.,		-		
5					
1					
1		EEB	A 0	1012	
		~ C 5	0 \dot{v}	في الله له، كم	7
2					
•					
1	. `	•			,
;					

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME		STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Research has demonstrated that IP-6 combined with inositol increases the activity of natural killer cells.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/3/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com Sincerely, Michael P. Jeven

Michael P. Devereux Chief Financial Officer

Celle Forte Max3 14e

January 7, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740 FEB 0 3 2003

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT. NAME		STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Maitake D-fraction also supports healthy natural killer cell development, macrophage activation, and cytotoxic T cell release.* These actions, in turn trigger production of interleukins and other lymphokines, chemicals that help mediate a healthy immune response.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: _

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/1/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Sincerely, P. Jevenn

Michael P. Devereux Chief Financial Officer Celle Forte Max3 18e

January 6, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

FEB 03 2003

COMPANY	PRODUCT . NAME	DIETARY	STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Specifically, maitake D-fraction supports healthy cell growth and function.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: _

Robert Doster Title: Senior Vice President of Scientific Affairs

Date: 1/4/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely, wein

Michael P. Devereux Chief Financial Officer

Celle Forte Max3 17e

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

January 12, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

FER OR COS

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>COMPANY</u>	PRODUCT NAME	DIETARY	STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Cat's claw POAs also increase B cells, resulting in an increased supply of antibodies.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: _1/12/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely. wein

Michael P. Devereux Chief Financial Officer

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Celle Forte Max3 23e

January 11, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

1 - 2 2 2 2 2 3 2

COMPANY	PRODUCT , NAME	DIETARY	STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Certain POAs increase the rate of macrophage phagocytosis and the production of interleukin secreted by macrophages.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Title: Senior Vice President of Scientific Affairs

Date: 1/11/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely P. Jeven

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com

Michael P. Devereux Chief Financial Officer

Celle Forte Max3 22e

January 5, 2003

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

FEB 0 3 2003

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME		STATEMENTS
Enzymatic Therapy, Inc.	Cell Forte® Max ³	IP-6 (inositol hexaphosphate), Inositol, Maitake Mushroom Extract, POA Cat's Claw (Uncaria tomentosa) Root Extract	Several maitake compounds have been identified, including the beta-glucan, maitake D- fraction. This branched polysaccharide has several immune health supportive functions.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/5/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

825 Challenger Drive Green Bay, WI 54311-8328 Ph: 920-469-1313 Fax: 888-570-6460 www.enzy.com Sincerely, Michael P. Jevenn

Michael P. Devereux Chief Financial Officer

Celle Forte Max3 16e